Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_84812EC41BE8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.
Périodique
Psychiatric Quarterly
Auteur(s)
Urben S., Baumann P., Barcellona S., Hafil M., Preuss U., Peter-Favre C., Clarke S., Halfon O., Holzer L.
ISSN
1573-6709 (Electronic)
ISSN-L
0033-2720
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
83
Numéro
3
Pages
311-324
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article
Publication Status: ppublish
Résumé
Twenty-three adolescents with psychotic disorders, aged from 13 to 18 years, participated in a 12-week open label trial (17 adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global Impression and Positive and Negative Symptom Scale (P's ≤ 0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed on one executive function (P = 0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction between quetiapine doses (>300 mg/day or <300 mg/day) and time, where lower doses showed more improvement in verbal short-term memory (P = 0.048), inhibition abilities (P = 0.038) and positive symptoms (P = 0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12 weeks of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition abilities and verbal short-term memory) and on positive symptoms.
Mots-clé
Adolescent, Adult, Analysis of Variance, Antipsychotic Agents/administration & dosage, Antipsychotic Agents/pharmacology, Cognition Disorders/drug therapy, Cognition Disorders/psychology, Dibenzothiazepines/administration & dosage, Dibenzothiazepines/pharmacology, Dose-Response Relationship, Drug, Female, Humans, Male, Neuropsychological Tests/statistics & numerical data, Nootropic Agents/administration & dosage, Nootropic Agents/pharmacology, Psychiatric Status Rating Scales/statistics & numerical data, Psychotic Disorders/drug therapy, Psychotic Disorders/psychology, Schizophrenia/drug therapy, Schizophrenic Psychology, Severity of Illness Index, Treatment Outcome
Pubmed
Web of science
Création de la notice
28/11/2011 17:44
Dernière modification de la notice
03/03/2018 18:55
Données d'usage